1. 1. Siegel RL, KD Miller, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin, 72(1): 7-33. [DOI:10.3322/caac.21708]

2. Dy GW, Gore JL, Forouzanfar MH, et al. (2017) Global Burden of Urologic Cancers, 1990-2013. Eur Urol, 71(3): 437-446. [DOI:10.1016/j.eururo.2016.10.008]

3. Amin MB, Greene FL, Edge SB, et al. (2017) The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin, 67(2): 93-99. [DOI:10.3322/caac.21388]

4. Avritscher EB, Cooksley CD, Grossman HB, et al. (2006) Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology, 68(3): 549-53. [DOI:10.1016/j.urology.2006.03.062]

5. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet, 388(10061): 2796-2810. [DOI:10.1016/S0140-6736(16)30512-8]

6. Bhindi B, Kool R, Kulkarni GS, et al. (2021) Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text. Can Urol Assoc J, 15(8): E424-e460. [DOI:10.5489/cuaj.7367]

7. Hiraoka N, Ino Y, Yamazaki-Itoh R (2016) Tertiary lymphoid organs in cancer tissues. Front Immunol, 7: 244. [DOI:10.3389/fimmu.2016.00244]

8. Meylan M, Petitprez F, Becht E, et al. (2022) Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity, 55(3): 527-541.e5. [DOI:10.1016/j.immuni.2022.02.001]

9. Horeweg N, Workel HH, Loiero D, et al. (2022) Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nat Commun, 13(1): 1373. [DOI:10.1038/s41467-022-29040-x]

10. Cabrita R, Lauss M, Sanna A, et al. (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature, 577(7791): 561-565. [DOI:10.1038/s41586-019-1914-8]

11. Patil NS, BY Nabet Müller S, et al. (2022) Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell, 40(3): 289-300.e4. [DOI:10.1016/j.ccell.2022.02.002]

12. Bai Z, Zhou Y, Ye Z, et al. (2021) Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. Front Immunol, 2021. 12: p. 808964. [DOI:10.3389/fimmu.2021.808964]

13. Schumacher TN and Thommen DS (2022) Tertiary lymphoid structures in cancer. Science, 375(6576): eabf9419. [DOI:10.1126/science.abf9419]

14. Wang B, Liu J, Han Y, et al. (2022) The Presence of Tertiary Lymphoid Structures Provides New Insight Into the Clinicopathological Features and Prognosis of Patients With Breast Cancer. Front Immunol, 13: p. 868155. [DOI:10.3389/fimmu.2022.868155]

15. Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer, 2012. 12(4): p. 298-306. [DOI:10.1038/nrc3245]

16. Koti M, Xu AS, Ren KYM, et al. (2017) Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer. Bladder Cancer, 3(4): 259-267. [DOI:10.3233/BLC-170120]

17. Lindskrog SV, Prip F, Lamy P, et al. (2021) An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun, 12(1): 2301. [DOI:10.1038/s41467-021-22465-w]

18. Nielsen JS, Sahota RA, Milne K, et al. (2012) CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res, 18(12): p. 3281-92. [DOI:10.1158/1078-0432.CCR-12-0234]

19. Kroeger DR, Milne K, BH Nelson (2016) tumor-infiltrating plasma cells Are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res, 22(12): 3005-15. [DOI:10.1158/1078-0432.CCR-15-2762]

20. Zhou L, Xu B, LiuY, Z. Wang (2021) Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer. Oncoimmunology, 10(1): 1915574. [DOI:10.1080/2162402X.2021.1915574]

21. An Y, Sun JX, Xu MY, et al. (2022) Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer. Front Immunol, 13: p. 1049884. [DOI:10.3389/fimmu.2022.1049884]

22. Faltas, BM, Prandi D, Tagawa ST, et al.(2016) Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet, 48(12): 1490-1499. [DOI:10.1038/ng.3692]

23. Hong H, Stastny M, Brown C, et al. (2014) Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J Immunother, 37(2): 93-104. [DOI:10.1097/CJI.0000000000000018]

24. Culpan M, Turan T, Ozkanli SS, et al. (2021) Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer. J Cancer Res Ther, 17(2): 434-442. [DOI:10.4103/jcrt.JCRT_408_19]

25. Li D, Zhong S, Zhu Z, et al. (2020) LncRNA MAFG-AS1 promotes the progression of bladder cancer by targeting the miR-143-3p/COX-2 axis. Pathobiology, 87(6): 345-355. [DOI:10.1159/000509957]

26. Wan GX, Chen P, Yu XJ, et al. (2015) Cyclooxygenase-2 polymorphisms and bladder cancer risk: a meta-analysis based on case-control studies. Int J Clin Exp Med, 8(3): 3935-45.

27. Gakis G (2014) The role of inflammation in bladder cancer. Adv Exp Med Biol, 816: 183-96. [DOI:10.1007/978-3-0348-0837-8_8]

28. Groeneveld CS, Fontugne J, Cabel L, et al.(2021) Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Eur J Cancer, 148: 181-189. [DOI:10.1016/j.ejca.2021.01.036]